1. Home
  2. BIIB vs ESLT Comparison

BIIB vs ESLT Comparison

Compare BIIB & ESLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BIIB
  • ESLT
  • Stock Information
  • Founded
  • BIIB 1978
  • ESLT 1966
  • Country
  • BIIB United States
  • ESLT Israel
  • Employees
  • BIIB N/A
  • ESLT N/A
  • Industry
  • BIIB Biotechnology: Pharmaceutical Preparations
  • ESLT Military/Government/Technical
  • Sector
  • BIIB Health Care
  • ESLT Industrials
  • Exchange
  • BIIB Nasdaq
  • ESLT Nasdaq
  • Market Cap
  • BIIB 24.2B
  • ESLT 22.6B
  • IPO Year
  • BIIB 1991
  • ESLT 1996
  • Fundamental
  • Price
  • BIIB $175.74
  • ESLT $468.97
  • Analyst Decision
  • BIIB Buy
  • ESLT Buy
  • Analyst Count
  • BIIB 23
  • ESLT 2
  • Target Price
  • BIIB $176.48
  • ESLT $530.00
  • AVG Volume (30 Days)
  • BIIB 2.0M
  • ESLT 102.9K
  • Earning Date
  • BIIB 10-30-2025
  • ESLT 11-18-2025
  • Dividend Yield
  • BIIB N/A
  • ESLT 0.57%
  • EPS Growth
  • BIIB N/A
  • ESLT 68.63
  • EPS
  • BIIB 10.97
  • ESLT 9.87
  • Revenue
  • BIIB $10,065,900,000.00
  • ESLT $7,720,284,000.00
  • Revenue This Year
  • BIIB $2.97
  • ESLT $18.56
  • Revenue Next Year
  • BIIB N/A
  • ESLT $11.03
  • P/E Ratio
  • BIIB $15.97
  • ESLT $49.62
  • Revenue Growth
  • BIIB 4.77
  • ESLT 18.35
  • 52 Week Low
  • BIIB $110.04
  • ESLT $243.18
  • 52 Week High
  • BIIB $176.02
  • ESLT $529.99
  • Technical
  • Relative Strength Index (RSI)
  • BIIB 76.31
  • ESLT 43.71
  • Support Level
  • BIIB $165.75
  • ESLT $463.00
  • Resistance Level
  • BIIB $170.78
  • ESLT $523.00
  • Average True Range (ATR)
  • BIIB 5.16
  • ESLT 15.50
  • MACD
  • BIIB 1.34
  • ESLT 0.11
  • Stochastic Oscillator
  • BIIB 98.74
  • ESLT 18.74

About BIIB Biogen Inc.

Biogen is an established biopharmaceutical company focused on treatments for neurological diseases and rare diseases. Its declining multiple sclerosis franchise is its largest revenue generator and contributed 45% of total revenue in 2024. Biogen also generates significant revenue from its CD20 collaboration agreements with Roche (18% of total in 2024), which includes oncology drugs Rituxan and Gazyva and multiple sclerosis drug Ocrevus. Biogen's newer franchises include Spinraza (spinal muscular atrophy, with partner Ionis), Leqembi (Alzheimer's disease, collabroation revenue from its partner Eisai), Skyclarys (Friedreich's ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (amyotrophic lateral sclerosis, Ionis).

About ESLT Elbit Systems Ltd.

Elbit Systems Ltd is a technology company involved in producing a portfolio of systems and products for aircraft, land, and naval applications. The company's products are used for defense, homeland security, and commercial flight capabilities. Its systems and solutions may be installed on new platforms, or it may perform a comprehensive modernization program to transform a platform. Elbit Systems gives instructions to its customers on the proper maintenance of its products and will provide support team specialists when the customer cannot fix a problem. The company markets its systems and products as a prime contractor or as a subcontractor to government, defense, and homeland security contractors world wide.

Share on Social Networks: